nicardipine has been researched along with Esophageal Achalasia in 1 studies
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.
Esophageal Achalasia: A motility disorder of the ESOPHAGUS in which the LOWER ESOPHAGEAL SPHINCTER (near the CARDIA) fails to relax resulting in functional obstruction of the esophagus, and DYSPHAGIA. Achalasia is characterized by a grossly contorted and dilated esophagus (megaesophagus).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Esophageal achalasia (EA) is a rare disease in man and animals and there are many discussions on its higher risk of esophageal cancer." | 5.30 | High incidence of esophageal cancer in esophageal achalasia by the oral administration of N-amyl-N-methylnitrosamine and its prevention by nicardipine hydrochloride in mice. ( Baskar, R; Fukuda, K; Hongyo, T; Kurooka, M; Li, LY; Matsuda, H; Miyata, M; Nakajima, H; Nomura, T; Sutoh, K, 1998) |
| "Esophageal achalasia (EA) is a rare disease in man and animals and there are many discussions on its higher risk of esophageal cancer." | 1.30 | High incidence of esophageal cancer in esophageal achalasia by the oral administration of N-amyl-N-methylnitrosamine and its prevention by nicardipine hydrochloride in mice. ( Baskar, R; Fukuda, K; Hongyo, T; Kurooka, M; Li, LY; Matsuda, H; Miyata, M; Nakajima, H; Nomura, T; Sutoh, K, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurooka, M | 1 |
| Hongyo, T | 1 |
| Nakajima, H | 1 |
| Baskar, R | 1 |
| Li, LY | 1 |
| Fukuda, K | 1 |
| Sutoh, K | 1 |
| Miyata, M | 1 |
| Matsuda, H | 1 |
| Nomura, T | 1 |
1 other study available for nicardipine and Esophageal Achalasia
| Article | Year |
|---|---|
High incidence of esophageal cancer in esophageal achalasia by the oral administration of N-amyl-N-methylnitrosamine and its prevention by nicardipine hydrochloride in mice.
Topics: Administration, Oral; Animals; Calcium Channel Blockers; Carcinogens; Carcinoma, Squamous Cell; Esop | 1998 |